Relapsed/Refractory HER2+ Metastatic Breast Cancer
This article reviews the recent development of HER2-targeted therapies with central nervous system (CNS) activity that may improve survival of patients with CNS metastases and prevent development of new CNS metastases. This article also features insights from oncology experts Adam M. Brufsky, MD, PhD; V. K. Gadi, MD, PhD; Sara A. Hurvitz, MD; and Neil M. Iyengar, MD.
Advertisement
Advertisement
Trending on CancerNetwork
1
Emerging Strategies in Prostate Cancer: Molecular Glues and T-Cell Engagers
2
BCMA-Directed Bispecific Antibodies Navigating a New Era in Relapsed/Refractory Multiple Myeloma
3
What’s The State of Immunotherapy, Transplantation in Hematologic Oncology?
4
NCCN Guidelines Add Novel Therapeutics to First-Line TNBC Armamentarium
5